Definium Therapeutics, Inc. is a late-stage clinical biopharmaceutical company focused on developing a new generation of psychedelic-based therapeutics to address underlying causes of psychiatric and neurological disorders. The company's lead product candidate, DT120 ODT (lysergide tartrate), is a proprietary pharmaceutically optimized orally disintegrating tablet formulation of LSD that acts as a partial agonist at serotonin-2A (5-HT2A) receptors. DT120 ODT utilizes Catalent's Zydis fast-dissolve technology for faster absorption, improved bioavailability, and reduced gastrointestinal side effects. Definium is advancing DT120 ODT through multiple Phase 3 clinical trials across generalized anxiety disorder (GAD), major depressive disorder (MDD), and posttraumatic stress disorder (PTSD). The company has no approved products and generates no revenue. It trades on Nasdaq under the symbol DFTX. Updated
Here are previews of four interesting companies set to report quarterly results before markets open on Monday.
Here's a quick look at six publicly traded companies developing ways to use psychedelics to treat mental health issues.
Definium Therapeutics, Inc. is a late-stage clinical biopharmaceutical company focused on developing a new generation of psychedelic-based therapeutics to address underlying causes of psychiatric and neurological disorders.
